The Boston Lung Cancer Survival Cohort

波士顿肺癌生存队列

• 批准号: 10603494
• 负责人: David C Christiani
• 金额: $ 123.12万
• 依托单位: HARVARD SCHOOL OF PUBLIC HEALTH
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-06-01 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10603494
• 关键词: Address; Adult; Air Pollution; Alternative Therapies; Archives; Award; Biological; Biological Markers; Boston; Cancer Center; Cancer Patient; Cancer Survivor; Cancer Survivorship; Cessation of life; Chest imaging; Clinical; Collaborations; Collection; Creativeness; DNA; Dana-Farber Cancer Institute; Data; Data Management Resources; Databases; Diagnosis; Diagnostic; Dimensions; Disease Progression; Education; Electronic Health Record; Enrollment; Environment; Environmental Exposure; Epidemiologic Methods; Epidemiology; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor; Epigenetic Process; Erlotinib; Evaluation; Funding; Gefitinib; General Hospitals; Genetic; Genomics; Grant; Health; Health Insurance; Heterogeneity; High Resolution Computed Tomography; Image; Immune checkpoint inhibitor; Immunotherapy; Income; Individual; Infrastructure; Interdisciplinary Study; International; Investigation; Laboratories; Leukocytes; Libraries; Longterm Follow-up; Lung; Lung Adenocarcinoma; Malignant Neoplasms; Malignant neoplasm of lung; Massachusetts; Measures; Medical Informatics; Meteorology; Methodology; Modeling; Molecular; Monitor; Mutation; Natural History; Neighborhoods; Newly Diagnosed; Non-Small-Cell Lung Carcinoma; Nucleic Acids; Occupational; Oncogenic; Output; Paper; Participant; Pathology; Patients; Peripheral; Phenotype; Plasma; Positron-Emission Tomography; Productivity; Prognostic Marker; Publishing; Pulmonary function tests; Quality of life; Questionnaires; RNA; ROS1 gene; Race; Recording of previous events; Research; Research Personnel; Resource Sharing; Resources; Risk Factors; Sampling; Serum; Smoking; Socioeconomic Status; Source; Specimen; Survivors; Therapeutic; Tissue Banks; Tissue Microarray; Tissue Survival; Tissues; Translational Research; Treatment outcome; Treatment-related toxicity; Tumor Tissue; U-Series Cooperative Agreements; Update; Urine; Work; X-Ray Computed Tomography; anticancer research; automated image analysis; biobank; bioinformatics infrastructure; built environment; cancer diagnosis; cancer epidemiology; cancer heterogeneity; cancer survival; cancer therapy; clinical investigation; cohort; comorbidity; data management; data repository; dietary; driver mutation; economic determinant; effective therapy; empowerment; epidemiologic discoveries; follow-up; genetic epidemiology; genotyped patients; improved; income insurance; indexing; innovation; lung cancer screening; method development; minority patient; mortality; multidisciplinary; mutational status; new technology; novel; novel therapeutic intervention; novel therapeutics; phenome; phenomics; predictive marker; prognostic; programs; pulmonary function; racial disparity; radiomics; recruit; repository; response; segregation; social determinants; socioeconomics; survival outcome; targeted treatment; traditional therapy; translational medicine; treatment disparity; treatment response; treatment strategy; tumor; vaping

The Boston Lung Cancer Survival (BLCS) cohort is a Cancer Epidemiology Cohort of more than 12,000 lung cancer cases enrolled at Massachusetts General Hospital and the Dana-Farber Cancer Institute since 1992. This rich resource enables research to understand lung cancer heterogeneity that has already identified valuable prognostic markers and stimulated new treatment strategies. For example, the BLCS supported the first discovery of the association between EGFR mutations and response to therapy with EGFR-tyrosine kinase inhibitors and enabled research on effective treatments for non-small cell lung cancer patients with ALK and ROS1 rearrangements. In 2017, the cohort evolved into a survivor epidemiology cohort that is sustained by a U01 grant until May 2023. Our progress during the first U01 funding cycle (2017–2022) is substantial—we have published over 100 papers, supported 6 new grants, and worked with 50 collaborators nationally and internationally. With the U01 award expiring soon, there is an urgency to renew to: 1) maintain this first and most comprehensive lung cancer survivor cohort with the longest follow-up period—an unmatched source of data for translational research; 2) establish an innovative, detailed phenotyping database via automated image analysis of high-resolution computed tomography, as well as a radiomics database; 3) enable the established infrastructure to facilitate internal and external investigators to pilot methodologic approaches that will turn into productive multidisciplinary project grants by focusing on survival and treatment toxicity; and 4) leverage the Dana-Farber/Harvard Cancer Center Lung Program resources for creative multidisciplinary collaborations focused on treatment outcomes. Renewed funding is also critical to recruit 2,500 new cases (for a total of 14,500 cases) to this already large cohort. New cases are vitally important to: 1) facilitate comparison of new treatments and traditional therapy as well as evaluation of new clinical investigation in an ever-changing therapeutic environment; 2) allow us to collect more cases with driver mutation data, as well as those treated with immune checkpoint inhibitors; 3) promote collection of repeated biological samples to support developing prognostic/predictive biomarkers; 4) allow us to collect detailed data enabling assessment of environmental determinants as well as racial and socioeconomic determinants of survival; and 5) empower our studies to identify radiomic, genomic, epigenetic, and other phenomic biomarkers, environmental determinants, and racial and socioeconomic determinants that are relevant to patient survival to guide improved lung cancer screening and treatment strategies. The BLCS is one of the largest lung cancer survival cohorts and encompasses a wealth of biomarker, tumor molecular characterization, imaging, lung function, genetic, epigenetic, traditional epidemiologic risk factor, and electronic health record data. With continued support, this comprehensive cohort will provide unique opportunities to explore predictors of lung cancer survival and treatment outcomes, catalyzing powerful translational research that improves the health of individuals with lung cancer.

波士顿肺癌生存（BLCS）队列是一个癌症流行病学队列， 自1992年以来，在马萨诸塞州总医院和Dana-Farber癌症研究所登记的癌症病例。 这一丰富的资源使研究能够了解肺癌的异质性， 有价值的预后标志物和刺激新的治疗策略。例如，BLCS支持 首次发现EGFR突变与EGFR-酪氨酸激酶治疗反应之间的相关性 抑制剂，并为ALK非小细胞肺癌患者的有效治疗进行了研究， ROS 1重排。2017年，该队列演变成一个幸存者流行病学队列，由一个 U 01补助金至2023年5月。我们在第一个U 01资助周期（2017-2022）取得了实质性进展-我们 发表了100多篇论文，支持了6项新的赠款，并与全国50名合作者合作， 化国际大随着U 01奖励即将到期，迫切需要更新：1）首先保持这一点， 最全面的肺癌幸存者队列，随访时间最长，是 用于转化研究的数据; 2）通过自动图像建立创新的详细表型数据库 高分辨率计算机断层扫描分析，以及放射组学数据库; 3）使建立 基础设施，以方便内部和外部调查人员试点方法，将变成 生产性多学科项目赠款，重点是生存和治疗毒性;和4）利用 Dana-Farber/哈佛癌症中心肺部项目资源，用于创造性的多学科合作 专注于治疗结果。新的供资对于招募2 500名新病例也至关重要（总共 14，500例），这已经很大的队列。新病例至关重要：1）便于比较新病例 治疗和传统治疗以及在不断变化的新的临床研究的评价 治疗环境; 2）允许我们收集更多具有驱动突变数据的病例，以及接受治疗的病例 与免疫检查点抑制剂; 3）促进重复生物样品的收集，以支持开发 预后/预测生物标志物; 4）使我们能够收集详细的数据，从而评估环境 决定因素以及生存的种族和社会经济决定因素; 5）使我们的研究能够 识别放射组学、基因组学、表观遗传学和其他表型生物标志物、环境决定因素和种族 以及与患者生存相关的社会经济决定因素，以指导改善肺癌筛查 和治疗策略。BLCS是最大的肺癌生存队列之一， 丰富的生物标志物、肿瘤分子表征、成像、肺功能、遗传、表观遗传、传统 流行病学危险因素和电子健康记录数据。在持续的支持下， 将为探索肺癌生存和治疗结果的预测因素提供独特的机会， 促进强大的转化研究，改善肺癌患者的健康。

项目成果

Prediagnosis Smoking Cessation and Overall Survival Among Patients With Non-Small Cell Lung Cancer.

非小细胞肺癌患者的诊断前戒烟和总体生存率。

• DOI: 10.1001/jamanetworkopen.2023.11966
• 发表时间: 2023-05-01
• 期刊: JAMA NETWORK OPEN
• 影响因子: 13.8
• 作者: Wang, Xinan;Romero-Gutierrez, Christopher W.;Kothari, Jui;Shafer, Andrea;Li, Yi;Christiani, David C.
• 通讯作者: Christiani, David C.

Automated temporalis muscle quantification and growth charts for children through adulthood.

成年后，儿童自动化的颞肌量化和生长图。

• DOI: 10.1038/s41467-023-42501-1
• 发表时间: 2023-11-09
• 期刊: NATURE COMMUNICATIONS
• 影响因子: 16.6
• 作者: Zapaishchykova, Anna;Liu, Kevin X.;Saraf, Anurag;Ye, Zezhong;Catalano, Paul J.;Benitez, Viviana;Ravipati, Yashwanth;Jain, Arnav;Huang, Julia;Hayat, Hasaan;Likitlersuang, Jirapat;Vajapeyam, Sridhar;Chopra, Rishi B.;Familiar, Ariana M.;Nabavidazeh, Ali;Mak, Raymond H.;Resnick, Adam C.;Mueller, Sabine;Cooney, Tabitha M.;Haas-Kogan, Daphne A.;Poussaint, Tina Y.;Aerts, Hugo J. W. L.;Kann, Benjamin H.
• 通讯作者: Kann, Benjamin H.

Deep learning to estimate lung disease mortality from chest radiographs.

• DOI: 10.1038/s41467-023-37758-5
• 发表时间: 2023-05-16
• 期刊: NATURE COMMUNICATIONS
• 影响因子: 16.6
• 作者: Weiss, Jakob;Raghu, Vineet K. K.;Bontempi, Dennis;Christiani, David C. C.;Mak, Raymond H. H.;Lu, Michael T. T.;Aerts, Hugo J. W. L.
• 通讯作者: Aerts, Hugo J. W. L.

Postdiagnosis BMI Change Is Associated with Non-Small Cell Lung Cancer Survival.

• DOI: 10.1158/1055-9965.epi-21-0503
• 发表时间: 2022-01
• 期刊: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
• 作者: Yuan Q;Du M;Loehrer E;Johnson BE;Gainor JF;Lanuti M;Li Y;Christiani DC
• 通讯作者: Christiani DC

Spirometry at diagnosis and overall survival in non-small cell lung cancer patients.

• DOI: 10.1002/cam4.4808
• 发表时间: 2022-12
• 期刊: CANCER MEDICINE
• 影响因子: 4
• 作者: Zhai, Ting;Li, Yi;Brown, Robert;Lanuti, Michael;Gainor, Justin F.;Christiani, David C.
• 通讯作者: Christiani, David C.